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Abstract – Background. Toxoplasma gondii is an obligate intracellular protozoan parasite of warm-blooded verte-
brates. Most infections in immunocompetent patients are asymptomatic. However, since 2000s, strains with particular
genetic proﬁles that differ from the known clonal type (type I, II, III), have been described. In French Guiana, these
strains are highly pathogenic in immunocompetent patients. They have deﬁned a new clinical entity called Amazonian
Toxoplasmosis. The present study aims to further improve our knowledge on the pathogenicity of these Amazonian
T. gondii strains in comparison with three reference strains using Swiss strain mice. With these data, we tried to estab-
lish a predictive virulence score to classify these strains, but also to correlate this virulence with the severity of the
disease in infected patients. Results. All the virulence indicators revealed that the Amazonian strains isolated in French
Guiana presented a high virulence proﬁle, but lower than the highly virulent type I reference RH strain. The ﬁndings
reveal differences in virulence between human and animal strains, but also between anthropized and wild strains.
Conclusion. In addition to being a clinically relevant animal model of Amazonian Toxoplasmosis, this model could
also provide a solid experimental basis for future studies aiming to investigate the underlying mechanisms of
Amazonian Toxoplasmosis disease.
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Re´sume´ – Virulence des souches atypiques de Toxoplasma gondii isolées en Guyane française chez un modèle
murin. Contexte. Toxoplasma gondii est un parasite protozoaire intracellulaire obligatoire des vertébrés à sang chaud.
La plupart des infections chez les patients immunocompétents sont asymptomatiques. Cependant, depuis les années
2000, des souches avec des proﬁls génétiques particuliers qui diffèrent du type clonal connu (type I, II, III) ont été
décrites. En Guyane française, ces souches sont hautement pathogènes chez les patients immunocompétents. Elles
ont déﬁni une nouvelle entité clinique appelée Toxoplasmose Amazonienne. La présente étude vise à approfondir
nos connaissances sur le pouvoir pathogène de ces souches amazoniennes de T. gondii par rapport à 3 souches de
référence en utilisant des souris de souche Swiss. Avec ces données, nous avons tenté d’établir un score de
virulence prédictif pour classer ces souches mais également de corréler cette virulence avec la gravité de la maladie
chez les patients infectés. Résultats. Tous les indicateurs de virulence ont révélé que les souches amazoniennes
isolées en Guyane française présentaient une virulence élevée mais plus faible que la souche de référence RH très
virulente de type I. Les résultats ont mis en évidence les différences de virulence entre les souches humaines et
animales mais aussi entre les souches anthropisées et les souches sauvages. Conclusion. En plus d’être un modèle
animal cliniquement pertinent de la toxoplasmose amazonienne, ce modèle pourrait également fournir une base
expérimentale solide à de futurs travaux qui chercheront à approfondir les mécanismes sous-jacents de la
toxoplasmose amazonienne.
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Introduction
Discovered since 1908 [38, 51], Toxoplasma gondii is a
parasite of warm-blooded vertebrates, including mammals, birds
and humans [17]. This obligate intracellular protozoan is a
cosmopolitan pathogen that is estimated to infect nearly one-
third of the adult human population [24]. Humans are contami-
nated either by consumption of raw or undercooked meat
containing tissue cysts or by accidental consumption of
oocyst-contaminated vegetables or drinking contaminated water
[23, 25, 29]. Until the last two decades, infection with T. gondii
was usually considered to cause no illness, but only some mild
clinical signs in immunocompetent individuals, speciﬁcally tran-
sient lymphadenopathy and mild ﬂu-like presentations. Severe
outcomes such as encephalitis, pneumonia, myocarditis, or dis-
seminated infections were uncommon. It is well-known that
infections acquired during pregnancy can result in mild to
serious congenital defects in the fetus, and potentially evolve
toward ocular infections [34, 40]. In immunocompromized indi-
viduals, such as transplant recipients and patients living with
HIV, toxoplasmosis can result in severe consequences, including
encephalitis, chorioretinitis, or myocarditis, which can poten-
tially be fatal [4]. Toxoplasma gondii strains isolated in North
America and Europe have been grouped into three major clonal
lineages as types I, II, and III, based on six genetic markers
[8, 26]. Several studies on experimental T. gondii infections have
reported a correspondence between virulence in mice and
genotype: type I strains such as RH are the most virulent with
a 100% lethal dose (LD100) of one parasite [47] less than 10 days
after inoculation. In contrast, type II strains such as PRU have
intermediate virulence (LD50 > 10
3), whereas type III strains
such as VEG are almost avirulent (LD50 > 10
5) [49]. There
may also be differences in the virulence of the three strains in
humans [4, 8, 26]. The development of genetic analyses by
RFLP-PCR [52] or microsatellites [5] showed more complex
polymorphism for several strains isolated from Africa [6, 19,
22, 37], Asia [28, 32, 42] and South America [45, 53].
However, despite this complex polymorphism, some of these
strains isolated from humans and animals can be grouped into
haplogroups corresponding to clonal lineages across these con-
tinents [30, 31, 33, 36]. In French Guiana, an Amazonian trop-
ical area, emerging strains exhibit high genetic diversity with
strains belonging to different haplogroups (HG). It revealed that
anthropized strains were closely grouped with HG3, while wild
strains were grouped with HG5 or HG10 [31]. These strains can
be responsible for a new clinical entity called Amazonian
Toxoplasmosis. This is a severe form of systemic acquired
toxoplasmosis among immunocompetent adults, with greater
potential for death [2, 3, 9, 10, 13–16, 37, 46].
The present study aimed to improve our knowledge of the
pathogenicity of these Amazonian T. gondii strains in compar-
ison with the three reference strains using a murine model, and
calculated mortality-linked parameters.
Materials and methods
Ethics statement
All experiments carried out in mice in this study were in
agreement with the recommendations of European Directive
No. 86/609/EEC and French Decree No. 2013-118. The exper-
imental protocols were approved by the Veterinary Services
Department and by the Ethics Committee of the Institut Pasteur
under the reference C2EA 89 – CETEA Institut Pasteur.
Experimental mice and parasites
Speciﬁc pathogen-free (SFP) Swiss CD1 mice were used
(Charles River Laboratory, Lyon, France), and they were bred
at the animal facility of Institut Pasteur de la Guyane.
In addition to the reference strains RH (type I), PRU (type II)
and VEG (type III), 10 T. gondii strains isolated in French
Guiana and genotyped by the microsatellite method (Table 1)
were provided by the Biological Resource Center of Limoges
(France). Five of them were isolated from patients and the other
ﬁve stains were isolated from wild or domestic animals [3, 15,
37]. The tachyzoites were cultured and harvested by serial
passages on monolayers of Human Foreskin Fibroblast cells
(HFF-1, ATCC number: SCRC-1041™) in Roswell Park
Memorial Institute medium (RPMI) 1640 with L-glutamine
(PAN Biotech GmbH, Aidenbach, Germany) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (PAN
Biotech GmbH, Aidenbach, Germany), penicillin (100 U/mL)
and streptomycin (100 lg/mL) (PAN Biotech GmbH, Aiden-
bach, Germany) at 37 C in a humid 5% CO2 atmosphere.
HFF-1 monolayers were infected by 105 tachyzoites and after
1 week, all cells were lyzed. The tachyzoites were scraped
and counted into a Kova cell chamber. The tachyzoites were
diluted to the appropriate concentration in sterile isotonic saline
(PBS). For each strain, different doses of tachyzoites ranging
from 5, 5  101, 5  102, 5  103 and 5  104 were respec-
tively inoculated intraperitoneally into groups of 10 mice
(Group 1, Group 2, Group 3, Group 4, and Group 5). The
parasite load of the inoculum was checked using Toxoplasma
real-time PCR (Bio-Evolution, Bry-sur-Marne, France), accord-
ing to the manufacturer’s recommendations.
Dose effect and mouse virulence tests
The virulence of T. gondii strains was determined by
monitoring clinical signs and cumulative mortality after peri-
toneal injection. We maintained 10 mice as uninfected controls
(Group 0) by injecting sterile isotonic saline (PBS). The mice
were clinically observed daily for 31 days. During the observa-
tion period, dead mice were counted. At the end of the obser-
vation period, live mice were counted and euthanized.
Toxoplasma infection was controlled using Toxoplasma real-
time PCR (Bio-Evolution) on the heart samples of the dead
or euthanized mice
Statistical analysis
Survival curve
Kaplan-Meier [41] plots were plotted, and the Log-rank test
was used to compare survival of mice and the mortality data
such as the mortality rate (MR) of the experimental groups.
p values 0.05 were considered signiﬁcant.
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Dose effect curve
The dose effect analysis was based on a probit regression to
model the impact of tachyzoite doses on the survival of a group
of mice. The analysis made it possible to determine LD50 and
LD99 which are respectively the required number of parasites
to kill 50% or 99% of infected mice. Statistical analyses and
graphics were performed using XLSTAT-Biomed [1].
Predictive score of virulence
Virulence is generally deﬁned as the intensity of an infec-
tious microorganism’s pathogenicity for its host. To better
deﬁne and objectively quantify T. gondii virulence in mice,
we determined a predictive virulence score for each strain.
For this, we used several parameters such as injected dose,
infected population, median number of days of survival after
infection, and mortality rate, and deﬁned the virulence score as:
Virulence score ðVSÞ
¼ Average
X 1
logðntachyÞ 
1
median survival
 
 ndeath  100
ninjected
   
ntachy: number of injected tachyzoites,
median survival: median of survival days per the number of
injected tachyzoites,
ndeath: number of mice that died per the injected dose,
ninjected: number of injected mice.
This score was used to objectively compare the different
T. gondii strains with each other, especially strains of unknown
virulence versus reference strains.
Table 1. Characteristics of the Toxoplasma gondii strains used in this study.
Isolate BRC code
number
MS genotype References Origin Host Patient symptoms
RH ND Type I [48] North
America
Human
PRU TgH00001 Type II [30] France Human
VEG TgH00005 Type III [48] North
America
Human
GUY-WAY-2007 TgH18028 Amazonian [37] Maripasoula
area*
Human Fever, persistent bronchitis
(severity: low)
Hospitalization
Favorable course with treatment
GUY-GRO-2011 TgH18049 Amazonian N.C. Maripasoula
area*
Human Fever, hepatitis (severity: intermediate)
Hospitalization
Favorable course with treatment
GUY-MEL-2003 TgH18007 Amazonian [37] Mana river* Human Fever, pneumopathy, heart damage
(severity: intermediate)
Hospitalization
Death from heart damage, 2 years after
treatment
GUY-AKO-2004 TgH18009 Amazonian [37] Apatou
area*
Human Fever, heart failure, anasarca
(severity: high)
Intensive care unit
Favorable course with treatment
GUY-TOJ-2006 TgH18021 Amazonian [37] Apatou
area*
Human Fever, general failure
(severity: very high)
Intensive care unit
Death despite treatment
GUY-CAN-FAM-0001 TgA18002 Caribbean1 [37] Macouria* Dog (Canis
familiaris)
GUY-CAN-FAM-0002 TgA18004 Caribbean2 [37] Macouria* Dog (Canis
familiaris)
GUY-CAN-FAM-0007 TgA18006 Amazonian [37] Roura* Dog (Canis
familiaris)
GUY-JAG-2004 TgA18001 Amazonian [37] Belizon
track*
Jaguar
(Panthera
onca)
GUY-GAL-VIT-0001 TgA18005 Single isolate [37] Matoury* Grison (Galictis
vittata)
Human Guyanese strains are classiﬁed by the severity of clinical signs observed. Animal strains are classiﬁed by the domestic or wild biotope.
N.C.: Not communicated.
* Sites localized in French Guiana.
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Results
The appearance of the disease in mice is characterized by
clinical signs (respiratory distress, rufﬂed hair, asthenia, slug-
gishness). Death occurs, in general, between 3 and 5 days after
the appearance of the ﬁrst signs. Autopsy of the mice showed
signiﬁcant damage to the heart, lungs and brain (data not
shown). These pathophysiological features are similar to those
seen in the most severely infected patients.
The presence of Toxoplasma gondii was veriﬁed by qPCR
on heart samples of all the mice (either dead during the exper-
iment, or euthanized after the 31 days of testing). All samples
were positive conﬁrming the presence of T. gondii in all mice.
Survival curves in infected mice
The differences of mice survival depending on the infecting
dose injected are shown in Figure 1. Unsurprisingly, we con-
ﬁrmed that the greater the injected dose, the higher the number
of deaths observed.
When 5 tachyzoites were injected, the RH and GUY-GRO-
2011 strains killed the entire group of mice in 12 days and 22
days, respectively. For the other Guianese strains, the MR was
less than or equal to 70% after 31 days except the GUY-GAL-
VIT0001 strain whose MR is 90% at 15 days. It was 20% and
0% after 31 days for the PRU (type II) and VEG (type III)
strains, respectively.
When 50 tachyzoites were injected, the GUY-CAN-
FAM0007 and GUY-GAL-VIT0001 strains killed the entire
group of mice in 18 days and 15 days, respectively. For 5
strains such as GUY-AKO-2004, GUY-TOJ-2006, GUY-
WAY-2007, GUY-CAN-FAM0002 and GUY-JAG-2004, the
MR was 90%. It was 40% and 10% for PRU and VEG strains,
respectively.
When 500 tachyzoites were injected, all the Guianese
strains had a 100% MR between 13 and 19 days, whereas
the PRU and VEG strains had mortality rates of 40% and
30%, respectively.
The higher the injected dose of tachyzoites, the shorter the
time to death (Table 2). The median survival time of mice
injected with 5 tachyzoites (minimum doses) for the RH strain
was 10.4 days (with an MR of 100%), 19.5 days for PRU (with
an MR of 20%), and there was no mortality for VEG. The
median survival time with 5 104 tachyzoites (maximum dose)
for the RH strain was 7.6 days (with anMR of 100%), 14.5 days
for PRU (with an MR of 50%), and 19 days for VEG (with an
MR of 40%). For Guianese strains, the median survival time
ranged between 12.1 (GUY-GAL-VIT0001) and 19.5 (GUY-
GRO-2011) days for a dose of 5 tachyzoites and between 8.6
(GUY-GAL-VIT0001) and 13.8 (GUY-CAN-FAM0002) days
for an inoculum of 5 104 tachyzoites injected (Table 2).
Determination of LD50 and LD99
The mortality rate (MR) of the mice after 31 days post
infection according to the strain is shown in Figure 2. The pro-
ﬁle of the three reference strains is very speciﬁc. The RH strain
showed a highly virulent proﬁle with 100% mortality for a very
small amount of injected tachyzoites. The PRU strain had a less
aggressive proﬁle with an MR between 20% and 50%, and the
VEG strain was almost as virulent because the mortality rate
varied from 0% to 40% for a number of injected tachyzoites
ranging from 5 to 5 104. We highlighted that, when compared
with the reference strains, the Guianese strains had proﬁles
close to the RH strains.
We used the line equation to calculate LD50 and LD99
which are respectively the required amount of parasites to kill
50% or 99% of infected mice (Table 3). The reference strains
RH, PRU and VEG had an LD50 of 1, 3933 and 126,373 tachy-
zoites, respectively and an LD99 of 4, 2  1013 and 1.5  1010
tachyzoites, respectively. French Guianese strains had an LD50
value ranging between 1 and 10 tachyzoites, and an LD99 value
between 7 and 1018 tachyzoites. These values conﬁrm the
virulent proﬁle of the Guianese strains.
Virulence score in mice
We ﬁrst determined the levels of virulence in murine mod-
els for the reference strains (Fig. 3). The highly virulent RH
strain corresponded to a high score of 5.89. The intermediate
virulent PRU strain had a score of 1.07, and the non-virulent
strain had a low score of 0.32.
We then compared the virulence scores with the severity of
the symptoms caused in infected patients. Patients were classi-
ﬁed with increasing severity (Table 1), thus virulence scores
should also increase. There was an increase in the score for
the ﬁrst four patients (GUY-WAY-2007, GUY-GRO-2011,
GUY-MEL-2003 and GUY-AKO-2004) who had a virulence
score of 3.01, 3.40, 3.48 and 3.55, respectively. However, the
last patient had the most severe symptoms (death), but his score
was only 3.28. We hypothesized that scores would increase
with increasing symptom severity in patients. This was con-
ﬁrmed in the ﬁrst four patients, but this increase was very
low compared to the symptoms in the different patients. The
difference in score between a patient with persistent bronchitis
and a patient in an intensive care unit was only 0.54.
The scores determined for the strains isolated from animals
were more heterogeneous ranging from 2.42 for the GUY-JAG-
2004 strain to 4.9 for the GUY-GAL-VIT0001 strain.
The Guianese strains ranged between the highly virulent
RH strain and the intermediate virulent PRU strain. This seems
to indicate rather high virulence especially for the GUY-GAL-
VIT0001 strain, which showed a very high score. However,
although its mortality rate was not the highest, its score was
high because the death of the mice occurred very quickly after
the injection.
Discussion
To our knowledge, the present experimental results on
Toxoplasma virulence in mice are original. Most articles
explore the virulence in mice from very speciﬁc approaches.
Some experiments are much more focused on analyzing the
correlation between clinical data and biological markers of
acute, chronic or secondary infections involving European or
North-American strains [27], while others attempt to demon-
strate the basic patterns of T. gondii pathophysiological
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Figure 1. Virulence in mice of atypical Toxoplasma gondii strains isolated in French Guiana compared to reference strains (type I, II and III).
Ten mice/groups were inoculated intraperitoneally with different doses of tachyzoites for each strain, and the viability of mice was monitored
daily. Survival was followed up for 31 days after injection and data were plotted as Kaplan-Meier curves (statistical signiﬁcance of survival
curves between RH and others strains, p  0.001).
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Figure 2. Determination of LD50 and LD99 for the 10 atypical strains of Toxoplasma gondii compared to reference strains (type I, II and III).
Dose effect curves using a Probit model (black). Conﬁdence interval (95%) curves are also shown (grey). On top of the ﬁgure, the tree
reference strains (I, II and III) are shown for comparison.
Table 2. Median survival days (±SD) of mice inoculated with different doses of parasites.
T. gondii strains
RH PRU VEG GUY-
AKO-
2004
GUY-
GRO-
2011
GUY-
MEL-
2003
GUY-
TOJ-
2006
GUY-
WAY-
2007
GUY-
CAN-
FAM
0001
GUY-
CAN-
FAM
0002
GUY-
CAN-
FAM
0007
GUY-
JAG-
2004
GUY-
GAL-
VIT
0001
Doses of
parasites
5  100 10.4 ± 0.5 19.5 ± 1.0 Undeﬁned 13.3 ± 2.0 19.5 ± 1.9 14.2 ± 1.2 15.7 ± 1.8 15.4 ± 1.5 13.3 ± 0.9 15.8 ± 1.7 15.3 ± 1.2 15.7 ± 1.5 12.1 ± 1.2
5  101 10.0 ± 0.3 18.3 ± 2.2 23 13.2 ± 1.2 16.5 ± 1.0 13.8 ± 1.0 14.4 ± 1.1 13.6 ± 0.5 14.0 ± 1.2 15.6 ± 1.3 14.9 ± 1.3 16.2 ± 1.3 12.0 ± 1.0
5  102 9.4 ± 0.7 16.8 ± 3.0 21 12.8 ± 1.7 15.3 ± 0.7 12.0 ± 0.7 14.3 ± 1.1 12.2 ± 1.0 13.4 ± 0.9 14.7 ± 1.5 12.4 ± 1.2 15.4 ± 1.0 10.4 ± 1.0
5  103 8.8 ± 0.7 16.2 ± 3.9 20.3 ± 3.5 11.5 ± 1.0 14.0 ± 0.7 11.1 ± 0.9 13.9 ± 1.3 10.9 ± 0.5 12.6 ± 1.8 14.8 ± 1.6 11.5 ± 0.9 14.4 ± 1.3 9.2 ± 0.8
5  104 7.6 ± 0.7 14.5 ± 2.8 19.0 ± 3.8 10.3 ± 1.4 12.1 ± 0.5 8.9 ± 0.9 11.7 ± 1.7 9.4 ± 0.5 11.9 ± 0.9 13.8 ± 1.5 9.6 ± 0.7 11.8 ± 0.8 8.6 ± 0.7
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mechanisms using transgenic mice [11, 19, 44] or other
advanced technologies, such as bioluminescence imaging [7].
Some general reviews reported data from experimental assays
and overviewed hypotheses underlying toxoplasma virulence
based on general comparisons between different genotypic
strains including the clonal reference ones [18, 21, 35, 50].
Recently, Saraf et al. [43], proposed a standardized methodology
for future studies in order to enable more efﬁcient and effective
analysis of genetics and virulence patterns for T. gondii.
Our study, despite being performed before the publication
of this article, complied with its instructions except for:
(i) the determination of seroconversion by modiﬁed agglutina-
tion test (MAT) as we used T. gondii qPCR to conﬁrm the
infection, (ii) the number of mice injected per group, 10 instead
of 5, in order to improve the performance and robustness of the
study, and (iii) the studied parameters, such as the determina-
tion of the DL100 and DL99, and calculated the cumulative
mortality rate using another approach. In fact, we concentrated
on determining a virulence score by considering several rele-
vant parameters such as the survival time, the amount of
injected tachyzoites, and the cumulative MR.
This parameter seemed to be an objective and useful tool to
evaluate virulence in mice. It matched with the other results of
this study and was validated by the good correspondence of its
values with clinical classes (virulent, intermediate and non-
virulent) for the reference strains. It could thus be used to
compare the strains among one another, especially strains
isolated from diverse geographical areas, and enabled us to
correlate the virulence of these strains with the clinical features
in humans, when there are human contaminations. We empha-
size that this experiment obviously cannot be extrapolated to
other experimental rodent species: susceptibility to T. gondii
infection varies among different hosts [12, 17] and laboratory
mice, generally sensitive, are often used as the preferred animal
model to determine parasite virulence.
The RH strain (type I) had a 100% mortality rate with ﬁve
injected tachyzoites. The PRU (type II) and VEG (type III)
strains did not have a 100% mortality rate. However, all these
Guianese strains had a 100% mortality rate with only 500
tachyzoites injected. This suggests that the atypical T. gondii
strains circulating in French Guiana have virulence factors
comparable to those established by the type I strain compared
to those of type II or type III. This ﬁtted with the results of
the virulence score. Regarding this parameter, we should high-
light the differences between strains isolated from humans and
animals, and even within the strains isolated from animals. It is
Figure 3. Scoring of virulence of Toxoplasma gondii strains isolated in French Guiana compared to reference strains type I, II and III. The ﬁrst
three strains are the reference strains, the next ﬁve strains are isolated from patients (with an increase in the severity of the symptoms), and the
last ﬁve strains are isolated from animals (three from domestic fauna and two from wildlife).
Table 3. Determination of LD50 and LD99.
T. gondii strains
RH PRU VEG GUY-
AKO-
2004
GUY-
GRO-
2011
GUY-
MEL-
2003
GUY-
TOJ-
2006
GUY-
WAY-
2007
GUY-
CAN-
FAM 0001
GUY-
CAN-
FAM 0002
GUY-CAN-
FAM0007
GUY-JAG-
2004
GUY-GAL-
VIT0001
DL50 1 3933 126,273 3 1 3 2 5 8 7 4 10 2
DL99 4 2E + 13 1.5E + 10 327 7 1018 745 465 561 217 12 182 9
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unclear whether this should be explained by the geographic
origin of the strains or by the type of intermediate or deﬁnitive
hosts clearly, recent studies revealed that in French Guiana,
there are two T. gondii environmental populations, the wild
population with very high genetic diversity, and the anthropized
population presenting lower genetic diversity [37].
Thus, in this study, the strains isolated from humans
(Amazonian type) showed elevated high virulence scores with
a median of 3.34, but lower than that of the RH strain (5.89).
According to patient surveys and their reported risk factors
[9, 16], these strains were related to wild environments.
Except for two patients who developed mild pneumopathy
(GUY-WAY-2007, GUY-MEL-2003), the others presented
severe infections with organ failure (heart, kidneys, liver,
lungs). Patients were classiﬁed by the degree of severity of
symptoms (Table 1). However, the classiﬁcation of patients
by severity was difﬁcult because other factors than the infecting
strain can inﬂuence the intensity of human disease (host genetic
factors, inocula, etc.). The low variation of the virulence score
between the patient with pneumopathy (GUY-WAY-2007) and
the patient with cardiac involvement (GUY-AKO-2004) did not
reveal an obvious correlation between the degree of severity
and the virulence score. In addition, the last patient had the
most serious symptoms but his score was one of the lowest
because this patient was already weakened during the
contamination, unlike the other four.
However, these scores are higher than for the PRU (type II)
strain, indicating fairly strong pathogenicity of these
Amazonian strains.
Concerning the animal strains, our ﬁndings reported a
heterogeneous virulence score. The lowest value was 2.42 and
concerned a strain isolated from a free-living Panthera onca,
GUY-JAG-2004 [15], while the highest value was 4.90 for
the GUY-GAL-VIT0001 strain isolated from a wild animal
(greater grison: Galictis vittata, Mustelidae) close to an anthro-
pized environment located on the thin coastal border (disturbed
forest near the city of Cayenne) [37]. A very high virulence
score comparable to that of human strains was calculated for
one strain isolated from a dog in the anthropized area
(GUY-CAN-FAM0007), whereas those from the other two dogs
presented intermediate virulence scores. These two strains which
genetically belong to the “Caribbean” 1 and 2 types (respec-
tively GUY-CAN-FAM0001 and GUY-CAN-FAM0002) have
been isolated essentially from animals circulating in anthropized
areas, and are genotypes that are found throughout the
Caribbean and part of South America. They are therefore
potentially strains imported by human activity into French
Guiana [37]. Little is known about the severity of the symptoms
caused by these strains in a contaminated patient. Although an
isolated case has demonstrated the opposite, we could expect
that they are presumably more symptomatic than those caused
by European strains, but still lack the speciﬁc severity of
Amazonian Toxoplasmosis according to several recorded cases
[16, 36].
The lower score of strain GUY-JAG-2004 was interesting
because this strain was typed “Amazonian” by Mercier et al.
[37]. This strain appeared to have a common ancestor with
the type II strain. In a recent classiﬁcation [33], Guianese strains
belong to haplogroups 5 and 10, grouped in clade F and
GUY-JAG-2004 is similar with microsatellite typing to a strain
isolated from cougars in Canada, belonging to HG11. These
strains belong to the ancestral clade D in which there are
type II strains. This may explain its lower virulence for mice.
Contrary to our expectations (we had predicted a very high
virulence score for the wild strains and a low virulence score for
the anthropized strains [36]); there was no obvious correlation
between ecological origin and virulence score. Such assays
seem interesting to classify strains, rank them by severity,
and have a better overview of their potential clinical severity,
especially in the case of strains for which little or no clinical
information in humans has yet been identiﬁed (e.g., Caribbean
strains).
Although the number of studied strains was low, the ﬁrst
results revealed that the Guianese strains had a higher virulence
than type II strains usually found in Europe and North America.
However, virulence is weaker than the highly virulent type I
strain. In addition, the study of a larger number of Amazonian
strains and reference strains would make it possible to verify
our model. Furthermore, the study of strains with a greater
number of mice could have an inﬂuence on the precision of
the virulence score. However, these experiments require the
use of a large number of mice, which raises ethical questions.
At present, there is not much information on the virulence
mechanisms of these Guianese strains. A study showed the
variation of polymorphic rhoptry protein kinases ROP18 and
ROP5 of Guianese strains with other strains [39]. Our model
would make it possible to develop reliable experimental tests
to better describe the genetic or immunological virulence fac-
tors of these Amazon strains.
In conclusion, the virulence indicators revealed that the
Amazonian strains presented a high virulence proﬁle, but
weaker than the highly virulent type I reference. There were dif-
ferences in virulence between human and animal strains, but
also between anthropized and wild strains. In addition to being
a clinically relevant animal model of Amazonian Toxoplasmo-
sis, this model could also provide a solid experimental basis for
future studies aiming to investigate the underlying pathophysi-
ology of Amazonian Toxoplasmosis.
Conflict of interest
The authors declare that there is no conﬂict of interest.
Acknowledgements. This work beneﬁted from an “Investissement
d’Avenir” grant managed by the French National Research Agency
(ANR) (CEBA, ref. ANR-10-LABX-25-01) and from a European
Regional Development Fund (ERDF) grant (FEDER présage n
30820).
References
1. Addinsoft. 2017. XLSTAT 2017: Logiciel de statistiques et
d’analyse de données pour Microsoft Excel. Paris, France:
Addinsoft.
2. Ajzenberg D, Cogne N, Paris L, Bessieres MH, Thulliez P,
Filisetti D, Pelloux H, Marty P, Dardé ML. 2002. Genotype of
86 Toxoplasma gondii isolates associated with human congen-
ital toxoplasmosis, and correlation with clinical ﬁndings.
Journal of Infectious Diseases, 186(5), 684–689.
8 S. Simon et al.: Parasite 2019, 26, 60
3. Ajzenberg D, Bañuls AL, Su C, Dumetre A, Demar M,
Carme B, Dardé ML. 2004. Genetic diversity, clonality and
sexuality in Toxoplasma gondii. International Journal for
Parasitology, 34(10), 1185–1196.
4. Ajzenberg D, Yera H, Marty P, Paris L, Dalle F, Menotti J,
Aubert D, Franck J, Bessieres MH, Quinio D, Pelloux H,
Delhaes L, Desbois N, Thulliez P, Robert-Gangneux F,
Kauffmann-Lacroix C, Pujol S, Rabodonirina M, Bougnoux
ME, Cuisenier B, Duhamel C, Duong TH, Filisetti D, Flori P,
Gay-Andrieu F, Pratlong F, Nevez G, Totet A, Carme B,
Bonnabau H, Dardé ML, Villena I. 2009. Genotype of 88
Toxoplasma gondii isolates associated with toxoplasmosis in
immunocompromised patients and correlation with clinical
ﬁndings. Journal of Infectious Diseases, 199(8), 1155–1167.
5. Ajzenberg D, Collinet F, Mercier A, Vignoles P, Dardé ML.
2010. Genotyping of Toxoplasma gondii isolates with 15
microsatellite markers in a single multiplex PCR assay. Journal
of Clinical Microbiology, 48(12), 4641–4645.
6. Al-Kappany YM, Rajendran C, Abu-Elwafa SA, Hilali M,
Su C, Dubey JP. 2010. Genetic diversity of Toxoplasma gondii
isolates in Egyptian feral cats reveals new genotypes. Journal of
Parasitology, 96(6), 1112–1114.
7. Avci P, Karimi M, Sadasivam M, Antunes-Melo WC,
Carrasco E, Hamblin MR. 2018. In-vivo monitoring of infec-
tious diseases in living animals using bioluminescence imaging.
Virulence, 9(1), 28–63.
8. Behnke MS, Khan A, Wootton JC, Dubey JP, Tang K, Sibley
LD. 2011. Virulence differences in Toxoplasma mediated by
ampliﬁcation of a family of polymorphic pseudokinases.
Proceedings of the National Academy of Sciences of the United
States of America, 108, 9631–9636.
9. Carme B, Bissuel F, Ajzenberg D, Bouyne R, Aznar C,
Demar M, Bichat S, Louvel D, Bourbigot AM, Peneau C,
Neron P, Dardé ML. 2002. Severe acquired toxoplasmosis in
immunocompetent adult patients in French Guiana. Journal of
Clinical Microbiology, 40(11), 4037–4044.
10. Carme B, Demar M, Ajzenberg D, Dardé ML. 2009. Severe
acquired toxoplasmosis caused by wild cycle of Toxoplasma
gondii, French Guiana. Emerging Infectious Diseases, 15(4),
656–658.
11. Cruz A, Mendes EA, de Andrade MV, do Nascimento VC,
Cartelle CT, Arantes RM, Melo JR, Gazzinelli RT, Ropert C.
2014. Mast cells are crucial in the resistance against Toxo-
plasma gondii oral infection. European Journal of Immunology,
44(10), 2949–2954.
12. Cunningham AA, Buxton D, Thomson KM. 1992. An epidemic
of toxoplasmosis in a captive colony of squirrel monkeys
(Saimiri sciureus). Journal of Comparative Pathology, 107(2),
207–219.
13. Dardé ML, Bouteille B, Pestre-Alexandre M. 1992. Isoenzyme
analysis of 35 Toxoplasma gondii isolates and the biological and
epidemiological implications. Journal of Parasitology, 78(5),
786–794.
14. Demar M, Ajzenberg D, Maubon D, Djossou F, Panchoe D,
Punwasi W, Valery N, Peneau C, Daigre JL, Aznar C,
Cottrelle B, Terzan L, Dardé ML, Carme B. 2007. Fatal
outbreak of human toxoplasmosis along the Maroni River:
epidemiological, clinical, and parasitological aspects. Clinical
Infectious Diseases, 45(7), 88–95.
15. Demar M, Ajzenberg D, Serrurier B, Dardé ML, Carme B.
2008. Atypical Toxoplasma gondii strain from a free-living
jaguar (Panthera onca) in French Guiana. American Journal of
Tropical Medicine and Hygiene, 78(2), 195–197.
16. Demar M, Hommel D, Djossou F, Peneau C, Boukhari R,
Louvel D, Bourbigot AM, Nasser V, Ajzenberg D, Dardé ML,
Carme B. 2012. Acute toxoplasmoses in immunocompetent
patients hospitalized in an intensive care unit in French Guiana.
Clinical Microbiology and Infection, 18(7), 221–231.
17. Dubey JP. 2010. Toxoplasmosis of Animals and Humans, 2nd
edn. Florida: Boca Raton. Book, Whole
18. Dubey JP, Rajendran C, Ferreira LR, Kwok OC, Sinnett D,
Majumdar D, Su C. 2010. A new atypical highly mouse virulent
Toxoplasma gondii genotype isolated from a wild black bear in
Alaska. Journal of Parasitology, 96(4), 713–716.
19. Dubey JP, Ferreira LR, Martins J, McLeod R. 2012. Oral
oocyst-induced mouse model of toxoplasmosis: effect of
infection with Toxoplasma gondii strains of different genotypes,
dose, and mouse strains (transgenic, out-bred, in-bred) on
pathogenesis and mortality. Parasitology, 139(1), 1–13.
20. Dubey JP, Choudhary S, Tilahun G, Tiao N, Gebreyes WA,
Zou X, Su C. 2013. Genetic diversity of Toxoplasma gondii
isolates from Ethiopian feral cats. Veterinary Parasitology, 196
(1–2), 206–208.
21. Dubey JP, Alvarado-Esquivel C, Herrera-Valenzuela VH,
Ortiz-Diaz JJ, Oliveira S, Verma SK, Choudhary S, Kwok
OC, Su C. 2013. A new atypical genotype mouse virulent strain
of Toxoplasma gondii isolated from the heart of a wild caught
puma (Felis concolor) from Durango, Mexico. Veterinary
Parasitology, 197(3–4), 674–677.
22. Galal L, Ajzenberg D, Hamidovic A, Durieux MF, Darde ML,
Mercier A. 2018. Toxoplasma and Africa: one parasite, two
opposite population structures. Trends in Parasitology, 34(2),
140–154.
23. Gotteland C, Gilot-Fromont E, Aubert D, Poulle ML, Dupuis E,
Darde ML, Forin-Wiart MA, Rabilloud M, Riche B, Villena I.
2014. Spatial distribution of Toxoplasma gondii oocysts in soil
in a rural area: inﬂuence of cats and land use. Veterinary
Parasitology, 205(3–4), 629–637.
24. Grigg ME, Sundar N. 2009. Sexual recombination punctuated
by outbreaks and clonal expansions predicts Toxoplasma gondii
population genetics. International Journal for Parasitology,
39(8), 925–933.
25. Guo M, Dubey JP, Hill D, Buchanan RL, Gamble HR, Jones JL,
Pradhan AK. 2015. Prevalence and risk factors for Toxoplasma
gondii infection in meat animals and meat products destined for
human consumption. Journal of Food Protection, 78(2), 457–476.
26. Howe DK, Sibley LD. 1995. Toxoplasma gondii comprises three
clonal lineages: correlation of parasite genotype with human
disease. Journal of Infectious Diseases, 172(6), 1561–1566.
27. Jensen KD, Camejo A, Melo MB, Cordeiro C, Julien L,
Grotenbreg GM, Frickel EM, Ploegh HL, Young L, Saeij JP.
2015. Toxoplasma gondii superinfection and virulence during
secondary infection correlate with the exact ROP5/ROP18
allelic combination. mBio, 6(2), e02280–e02314.
28. Jiang HH, Huang SY, Zhou DH, Zhang XX, Su C, Deng SZ,
Zhu XQ. 2013. Genetic characterization of Toxoplasma gondii
from pigs from different localities in China by PCR-RFLP.
Parasites & Vectors, 6, 227–231.
29. Karanis P, Aldeyarbi HM, Mirhashemi ME, Khalil KM. 2013.
The impact of the waterborne transmission of Toxoplasma
gondii and analysis efforts for water detection: an overview and
update. Environmental Science and Pollution Research Interna-
tional, 20(1), 86–99.
30. Khan A, Fux B, Su C, Dubey JP, Dardé ML, Ajioka JW,
Rosenthal BM, Sibley LD. 2007. Recent transcontinental sweep
of Toxoplasma gondii driven by a single monomorphic
chromosome. Proceedings of the National Academy of Sciences
of the United States of America, 104, 14872–14877.
31. Khan A, Ajzenberg D, Mercier A, Demar M, Simon S, Darde
ML, Wang Q, Verma SK, Rosenthal BM, Dubey JP, Sibley LD.
2014. Geographic separation of domestic and wild strains of
Toxoplasma gondii in French Guiana correlates with a
S. Simon et al.: Parasite 2019, 26, 60 9
monomorphic version of chromosome 1a. PLoS Neglected
Tropical Diseases, 8(9), e3182.
32. Li M, Mo XW, Wang L, Chen H, Luo QL, Wen HQ, Wei W,
Zhang AM, Du J, Lu FL, Lun ZR, Shen JL. 2014. Phylogeny
and virulence divergency analyses of Toxoplasma gondii
isolates from China. Parasites & Vectors, 7, 133.
33. Lorenzi H, Khan A, Behnke MS, Namasivayam S, Swapna LS,
Hadjithomas M, Karamycheva S, Pinney D, Brunk BP, Ajioka
JW, Ajzenberg D, Boothroyd JC, BoyleJP Dardé ML, Diaz-
Miranda MA, Dubey JP, Fritz HM, Gennari SM, Gregory BD,
Kim K, Saeij JP, Su C, White MW, Zhu XQ, Howe DK,
Rosenthal BM, Grigg ME, Parkinson J, Liu L, Kissinger JC,
Roos DS, Sibley LD. 2016. Local admixture of ampliﬁed
anddiversiﬁed secreted pathogenesis determinants shapes
mosaic Toxoplasma gondii genomes. Nature Communications,
7, 10147.
34. McAuley JB. 2014. Congenital Toxoplasmosis. Journal of the
Pediatric Infectious Diseases Society, 3(Suppl 1), S30–S35.
35. Melo RPB, Almeida JC, Lima DCV, Pedrosa CM, Magalhaes
FJR, Alcantara AM, Barros LD, Vieira RFC, Garcia JL, Mota
RA. 2016. Atypical Toxoplasma gondii genotype in feral cats
from the Fernando de Noronha Island, northeastern Brazil.
Veterinary Parasitology, 224, 92–95.
36. Mercier A, Devillard S, Ngoubangoye B, Bonnabau H, Banuls
AL, Durand P, Salle B, Ajzenberg D, Dardé ML. 2010.
Additional haplogroups of Toxoplasma gondii out of Africa:
population structure and mouse-virulence of strains from
Gabon. PLoS Neglected Tropical Diseases, 4(11), e876.
37. Mercier A, Ajzenberg D, Devillard S, Demar MP, de Thoisy B,
Bonnabau H, Collinet F, Boukhari R, Blanchet D, Simon S,
Carme B, Dardé ML. 2011. Human impact on genetic diversity
of Toxoplasma gondii: example of the anthropized environment
from French Guiana. Infection, Genetics and Evolution, 11(6),
1378–1387.
38. Nicolle C, Manceaux L. 1909. Sur un protozoaire nouveau du
gondi. Comptes Rendus Hebdomadaires des Séances de
l’Académie des Sciences, 148, 368–372.
39. Niedelman W, Gold DA, Rosowski EE, Sprokholt JK, Lim D,
Farid Arenas A, Melo MB, Spooner E, Yaffe MB, Saeij JP.
2012. The rhoptry proteins ROP18 and ROP5 mediate
Toxoplasma gondii evasion of the murine, but not the human,
interferon-gamma response. PLoS Pathogens, 8(6), e1002784.
40. Pleyer U, Schluter D, Manz M. 2014. Ocular toxoplasmosis:
recent aspects of pathophysiology and clinical implications.
Ophthalmic Research, 52(3), 116–123.
41. Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B,
Wang EW. 2010. A practical guide to understanding Kaplan-
Meier curves. Otolaryngology-Head and Neck Surgery, 143(3),
331–336.
42. Salant H, Hamburger J, King R, Baneth G. 2013. Toxoplasma
gondii prevalence in Israeli crows and Griffon vultures.
Veterinary Parasitology, 191(1–2), 23–28.
43. Saraf P, Shwab EK, Dubey JP, Su C. 2017. On the determi-
nation of Toxoplasma gondii virulence in mice. Experimental
Parasitology, 174, 25–30.
44. Seng S, Yokoyama M, Suzuki R, Maki Y, Kato M, Lim C,
Zayatiin B, Inoue N, Xuan X, Igarashi I, Nagasawa H, Fujisaki
K, Mikami T, Suzuki N, Toyoda Y. 2000. Expression of SAG-1
of Toxoplasma gondii in transgenic mice. Parasitology
Research, 86(4), 263–269.
45. Shwab EK, Zhu XQ, Majumdar D, Pena HF, Gennari SM,
Dubey JP, Su C. 2014. Geographical patterns of Toxoplasma
gondii genetic diversity revealed by multilocus PCR-RFLP
genotyping. Parasitology, 141(4), 453–461.
46. Shwab EK, Saraf P, Zhu XQ, Zhou DH, McFerrin BM,
Ajzenberg D, Schares G, Hammond-Aryee K, van Helden P,
Higgins SA, Gerhold RW, Rosenthal BM, Zhao X, Dubey JP,
Su C. 2018. Human impact on the diversity and virulence of the
ubiquitous zoonotic parasite Toxoplasma gondii. Proceedings of
the National Academy of Sciences of the United States of
America, 115(29), E6956–E6963.
47. Sibley LD, Boothroyd JC. 1992. Virulent strains of Toxoplasma
gondii comprise a single clonal lineage. Nature, 359(6390),
82–85.
48. Sibley LD, Mordue DG, Su C, Robben PM, Howe DK. 2002.
Genetic approaches to studying virulence and pathogenesis in
Toxoplasma gondii. Philosophical transactions of the Royal
Society of London. Series B, Biological sciences Royal Society
(Great Britain), 357(1417), 81–88.
49. Sibley LD, Ajioka JW. 2008. Population structure of Toxo-
plasma gondii: clonal expansion driven by infrequent recom-
bination and selective sweeps. Annual Review of Microbiology,
62, 329–351.
50. da Silva JR, Maciel BM, de Santana Souza Santos LKN,
Carvalho FS, de Santana Rocha D, Lopes CWG, Albuquerque
GR. 2017. Isolation and genotyping of Toxoplasma gondii in
Brazilian dogs. Korean Journal of Parasitology, 55(3), 239–246.
51. Splendore A. 1908. Un nuovo protozoa parassita deconigli
incontrato nelle lesioni anatomiche d’une malattia che ricorda in
molti punti il Kalaazar dell’uoma, Nota preliminare pel. Revista
da Sociedade Scientíﬁca de São Paulo, 3, 109–112.
52. Su C, Zhang X, Dubey JP. 2006. Genotyping of Toxoplasma
gondii by multilocus PCR-RFLP markers: a high resolution and
simple method for identiﬁcation of parasites. International
Journal for Parasitology, 36(7), 841–848.
53. Vitaliano SN, Soares HS, Minervino AH, Santos AL, Werther
K, Marvulo MF, Siqueira DB, Pena HF, Soares RM, Su C,
Gennari SM. 2014. Genetic characterization of Toxoplasma
gondii from Brazilian wildlife revealed abundant new geno-
types. International Journal for Parasitology: Parasites and
Wildlife, 3(3), 276–283.
Cite this article as: Simon S, de Thoisy B, Mercier A, Nacher M & Demar M. 2019. Virulence of atypical Toxoplasma gondii strains
isolated in French Guiana in a murine model. Parasite 26, 60.
10 S. Simon et al.: Parasite 2019, 26, 60
An international open-access, peer-reviewed, online journal publishing high quality papers
on all aspects of human and animal parasitology
Reviews, articles and short notes may be submitted. Fields include, but are not limited to: general, medical and veterinary parasitology;
morphology, including ultrastructure; parasite systematics, including entomology, acarology, helminthology and protistology, andmolecular
analyses; molecular biology and biochemistry; immunology of parasitic diseases; host-parasite relationships; ecology and life history of
parasites; epidemiology; therapeutics; new diagnostic tools.
All papers in Parasite are published in English. Manuscripts should have a broad interest and must not have been published or submitted
elsewhere. No limit is imposed on the length of manuscripts.
Parasite (open-access) continues Parasite (print and online editions, 1994-2012) and Annales de Parasitologie Humaine et Comparée
(1923-1993) and is the official journal of the Société Française de Parasitologie.
Editor-in-Chief: Submit your manuscript at
Jean-Lou Justine, Paris http://parasite.edmgr.com/
S. Simon et al.: Parasite 2019, 26, 60 11
